The growth potential of the Asian pharmaceutical and bio market is being highlighted, drawing increased interest from domestic companies. Celltrion, which has focused on advanced markets such as the United States and Europe, is now also targeting the Asian region. Notably, there are clear achievements in the ASEAN Pharmerging market, which includes Vietnam, Singapore, and Indonesia.
The ASEAN pharmaceutical market was valued at approximately KRW 40.4 trillion (USD 29 billion) as of 2023. According to the industry, it is expected to grow at an average annual rate of about 6% until 2030. Among these, Vietnam has formed a pharmaceutical market worth KRW 10 trillion, growing at an average annual rate of over 7% over the past decade. This growth has propelled Vietnam to emerge as a representative Pharmerging country in ASEAN.

Celltrion is focusing on this potential by leading the Vietnamese market with autoimmune disease treatments and anticancer drugs. Through its local subsidiary, it launched its main autoimmune disease treatment 'Remsima (ingredient name: infliximab)' and breast and stomach cancer treatment 'Herzuma (trastuzumab)' in June and August of this year, respectively. Upon launch, it signed supply contracts with the largest military hospital and medical institutions in the central and southern regions, thereby intensifying its market penetration. In the second half of this year, it plans to obtain local approvals and launch the subcutaneous injection formulation autoimmune disease treatment 'Remsima SC' and the blood cancer treatment 'Truxima'. The company is rapidly expanding its portfolio to accelerate market penetration.
Celltrion operates local subsidiaries in eight Asian countries, including Japan, Vietnam, Singapore, and Thailand, selling major products. Among these, the Singapore market, known as the ASEAN pharmaceutical and bio hub, is noteworthy. Significant achievements across its product range have been confirmed. According to pharmaceutical market research firm IQVIA, as of the first quarter of this year, the market share of the Remsima product line (IV, SC) in Singapore reached a remarkable 97%. Truxima recorded 70%, and Herzuma 37%, securing a dominant position in both autoimmune disease treatments and anticancer drugs. In another major market within the ASEAN region, Thailand, Herzuma's market share was recorded at 93%. The Remsima product line also showed a trajectory, reaching about 30%. Herzuma led the market in Malaysia with a 52% market share.

Celltrion aims to maintain its competitive edge in the ASEAN bidding market by leveraging product competitiveness and supply stability and to continue its prescription achievements by deploying sales strategies tailored to the characteristics of each country's pharmaceutical market.
Achievements in Japan, considered a global key market in Asia, are also noteworthy. The positive results are attributed to a customized sales strategy where Celltrion's local subsidiary and local partners each conduct sales, based on the Japanese government's biosimilar support policy. According to IQVIA and local market data, Herzuma recorded a 75% market share in Japan (as of April this year), maintaining the top prescription spot for four consecutive years.

The metastatic colorectal and breast cancer treatment Vegzelma (bevacizumab), launched in 2023, is also rapidly expanding its market presence with a 29% market share. Notably, Vegzelma, despite being the latest entrant among the six bevacizumab products sold in Japan, has narrowed the gap with the top-prescribed product to about 2% by leveraging marketing capabilities and product competitiveness.

A Celltrion representative stated, "Celltrion's product prescriptions are expanding not only in advanced medical countries like Europe and the United States but also in the representative Pharmerging market of Asia, and we are strengthening our portfolio by introducing follow-up products. With a commitment to providing high-quality biopharmaceutical benefits to more patients and enhancing the status of K-bio in the Asian region, we will continue to focus on sales activities based on local customized sales strategies and a stable supply chain."

Popular News